As of 2026, Wegovy (semaglutide) is a mature, mainstream option on the UK market for adults who need help to lose weight alongside diet, exercise, and behavioural support
Months 4-6: Steady progress During this period, most people reach their maintenance dose (10 mg, 12.5 mg, or 15 mg)
Because the drug leaves your system gradually, your hunger will likely return gradually as well giving you a window of opportunity to solidify your nutrition plan
Contact your healthcare provider if you experience pain that is severe, persistent, or affecting your ability to eat, drink, or stay hydrated
Uninsured) Both insured and uninsured patients may be eligible for the Wegovy Patient Assistance Program
This data confirms that semaglutide stands apart as the only available GLP-1-based medication with proven cardiovascular benefits for people living with obesity and cardiovascular disease, without diabetes. Additionally, in all treated people, regardless of any gaps in their treatment, people treated with Wegovy experienced fewer events of heart attack, stroke and cardiovascular-related death than people treated with tirzepatide
.png&w=828&q=100)
